Notice to the extraordinary general meeting to resolve a fully underwritten Rights Issue of NOK 70 million NewsKristin EivindvikNovember 17, 2016
PCI Biotech convenes an extraordinary general meeting to propose a fully underwritten Rights Issue of NOK 70 million NewsKristin EivindvikNovember 17, 2016
PCI Biotech to present poster at the ESMO Symposium on Immuno-Oncology 2016 NewsKristin EivindvikNovember 4, 2016
Results from the bile duct cancer study will be presented as late-breaking news at United European Gastroenterology Week NewsKristin EivindvikOctober 17, 2016
PCI Biotech to present poster at the Second International Cancer Immunotherapy Conference NewsKristin EivindvikSeptember 23, 2016
PCI Biotech to present phase I results at Nordic Life Science Days 2016 NewsKristin EivindvikSeptember 13, 2016
Independent evaluation confirms early promising signs of efficacy in the phase I/II bile duct cancer study NewsKristin EivindvikSeptember 6, 2016
PCI Biotech and BioNTech initiates preclinical research collaboration NewsKristin EivindvikSeptember 1, 2016
PCI Biotech granted Orphan Drug Designation of fimaporfin for treatment of cholangiocarcinoma in EU NewsKristin EivindvikAugust 29, 2016
Invitation to second quarter and first half year 2016 presentation NewsKristin EivindvikAugust 24, 2016
Publication of the fimaporfin (Amphinex) first-in-man Phase I study in Lancet Oncology NewsKristin EivindvikJuly 28, 2016
PCI Biotech receives positive opinion for Orphan Drug Designation of fimaporfin for treatment of cholangiocarcinoma in EU NewsKristin EivindvikJuly 26, 2016
